Loading...
OTCM
SKVI
Market cap1mUSD
Jul 09, Last price  
0.22USD
1D
0.00%
1Q
-31.25%
Jan 2017
1,275.00%
Name

Skinvisible Inc

Chart & Performance

D1W1MN
OTCM:SKVI chart
P/E
P/S
59.44
EPS
Div Yield, %
Shrs. gr., 5y
3.73%
Rev. gr., 5y
-40.82%
Revenues
20k
0.00%
777,685767,600287,269229,175229,175180,185270,29866,69654,923174,635108,890629,02769,34743,166275,556663,426279,29620,00020,00020,000
Net income
-1m
L+88.11%
-1,606,922-1,640,877-1,747,696-1,073,037-1,073,037-1,360,485-1,452,421-1,343,443-1,926,333-1,990,211-2,050,847-1,826,808158,342-2,722,287-2,641,559-2,285,796-2,211,342-2,382,440-565,654-1,064,034
CFO
-38k
L-45.00%
-862,075-743,872-947,355-350,50717,330-192,460-538,904-751,654-1,167,723-852,735-244,382-13,875-34,325-128,21245,765374,60545,170-77,157-69,834-38,410

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Skinvisible, Inc., together with its associated entities, specializes in the creation, production, and distribution of advanced polymer-based delivery system technologies. These proprietary systems facilitate the topical, transdermal, and mucosal application of active ingredients, serving various sectors including pharmaceuticals (both prescription and over-the-counter), personal skincare, and cosmetics. Beyond dermatological applications, the company's non-dermatological formulations address specific needs in women's health, pain management, and other diverse markets. Under the 'Skinbrella' brand, Skinvisible provides consumer products such as sunless tanning lotions and sunscreens. Their business model also encompasses licensing these technologies to pharmaceutical and consumer goods companies. Furthermore, they assist pharmaceutical clients with early-stage formulation development. A key service involves reformulating existing pharmaceutical products nearing patent expiration, utilizing their unique Invisicare patent to introduce new product benefits and facilitate line extensions. Incorporated in 1998, the company originally operated as Microbial Solutions, Inc. before adopting the name Skinvisible, Inc. in February 1999. It maintains its headquarters in Las Vegas, Nevada.
IPO date
Jan 07, 1999
Employees
2
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT